EyePoint tumbles after experimental eye drug misses main goal in late-stage study
BUZZ-EyePoint tumbles after experimental eye drug misses main goal in late-stage study ** Shares of drug developer EyePoint EYPT.O fell 62.7% to $5.50 premarket
** Co says experimental eye drug Duravyu missed the main goal of a late-stage trial against Regeneron's blockbuster eye drug Eylea in patients with wet age-related macular degeneration, a leading cause of vision loss
** EYPT says an analysis excluding nine patients whose vision loss was unrelated to wet AMD showed Duravyu performed similarly to Eylea
** Co says Duravyu reduced treatment burden by 42% versus Eylea, or about two fewer injections through Week 56
** EYPT says 54% of patients were supplement-free through Week 56 and 79% received zero or one supplemental injection
** Co expects data from a second late-stage wet AMD study in Q4 2026 and plans a potential FDA filing in H1 2027
** As of last close, stock down ~19% YTD
(Reporting by Sahil Pandey in Bengaluru)
Recent news on Regeneron Pharmaceuticals
See all newsEyePoint to halve workforce after experimental drug fails second late-stage trial (updated)
EyePoint to cut workforce by half after experimental drug fails second late-stage trial
Brief: Sanofi, pCPA Sign Letter Of Intent For Dupixent® Across Four Indications In Dermatology, Respiratory Care
Brief: Regeneron Pharmaceuticals Says Pasatru Shows Sustained Efficacy & Consistent Safety Profile From Weeks 56 To 84
Brief: Regeneron Pharmaceuticals - Sanofi Enter Sixth Amendment To License And Collaboration Agreement